This program is designed for rheumatologists, primary care physicians, and other clinicians involved in the screening and treatment of patients with rheumatoid arthritis.
The goal of this program is to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in rheumatoid arthritis.
Learning Objective (s)
- Describe the importance of early diagnosis of rheumatoid arthritis, and recent advances in our understanding of mechanisms that may serve as targets of therapy.
- Evaluate criteria that have been developed to assess treatment response in rheumatoid arthritis, delineate how these criteria can be used to risk-stratify patients in clinical practice, and consider therapeutic treatment options that improve patient outcomes.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Projects In Knowledge® designates this for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To obtain credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that all those who have control of the content of CE activities comply with the ACCME’s Standards for Commercial Support regarding disclosure of relevant financial relationships. Faculty, planners, PIK editorial scientific team, reviewers, and medical writers are required to disclose any financial relationship they or their spouse/partner have with any ACCME-defined commercial interest* relevant to the content of this activity. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed during the presentations.
M. Elaine Husni, MD, MPH M. Elaine Husni, MD, MPH, has received consulting fees from AbbVie, Inc., Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Inc., Pfizer Inc, Regeneron, and UCB, Inc.
Jeffrey R. Curtis, MD, MS, MPH has disclosed: Salary/honoraria: Roche/Genentech, UCB, Centocor, Corrona, Amgen, Pfizer, BMS, Crescendo, Abbott
Daniel Furst, MD, MSPH has received contracted research support from AbbVie Inc, Amgen Inc, Actelion Pharmaceuticals US, Inc, Bristol-Myers Squibb, Corbus Pharmaceuticals, NIH, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Roche/Genentech; and has received consulting fees from AbbVie Inc, Amgen Inc, Actelion Pharmaceuticals US, Inc, Bristol-Myers Squibb, Cytori Therapeutics, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc, and Roche/Genentech.
Aprajita Jagpal, MBBS, MD has disclosed no relevant relationships.
John R. P. Tesser, MD has received grant/research support from AbbVie, Inc, Ablynx, Amgen Inc, Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Janssen, Lilly, Novartis Pharmaceuticals, Pfizer Inc, Sandoz, and UCB Inc.; is on the speaker’s bureau for AbbVie, Inc, Amgen Inc, Bristol-Myers Squibb, Crescendo Biosciences, Genentech, Janssen, Lilly, Medac, and Pfizer Inc.; and is a consultant for/on the advisory board of Amgen Inc, Bristol-Myers Squibb, Crescendo Biosciences/Mallinkrodt, Genentech, Janssen, Lilly, Medac, Pfizer Inc., UCB Inc., and Sanofi-Genzyme/Regeneron.
Michael H. Weisman, MD has received consulting fees from Ampel Biosolutions LLC, Ionis Pharmaceuticals, and UCB, Inc.; and has received expert witness fees from Tharpe & Howell and Paul Hastings LLP.
Peer Reviewer has disclosed no relevant relationships.
Projects In Knowledge's staff members have no relevant relationships to disclose.
These activities may contain discussions of unlabeled/unapproved uses of drugs or devices. Specific product disclosure will be forthcoming in each activity.
The opinions expressed in these activities are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.